SCHEMBL4453054

SCHEMBL4453054

CS(=O)(=O)c1cccc(N(c2cccc(Cl)n2)C(c2cccnc2)c2cccnc2)c1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 1/20 0.38
CYP3A4 P08684 3/20 0.35
KDM4C Q9H3R0 1/20 0.35
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
LRRK2 Q5S007 1/20 0.34
GRM2 Q14416 3/20 0.34
CYP3A5 P20815 1/20 0.34
KCNE1 P15382 1/20 0.34
KCNA5 P22460 1/20 0.34
KCNQ1 P51787 1/20 0.34
KCND3 Q9UK17 1/20 0.34
PDE4B Q07343 2/20 0.33
VNN1 O95497 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4463302 0.94 TAAR1 (0.35) TAAR1CYP3A4KDM4CPTGS1PTGS2
SCHEMBL4472831 0.87 TAAR1 (0.38) TAAR1KDM4CLRRK2GRM2KCNE1
SCHEMBL4460408 0.84 NFE2L2 (0.42) TAAR1CYP3A4PTGS1PTGS2CYP3A5
SCHEMBL4460584 0.84 TAAR1 (0.44) TAAR1KDM4CPTGS2LRRK2GRM2
SCHEMBL4472068 0.83 TAAR1 (0.39) TAAR1CYP3A4PTGS1PTGS2LRRK2
SCHEMBL4461909 0.83 TAAR1 (0.39) TAAR1CYP3A4KDM4CPTGS1PTGS2
SCHEMBL4464155 0.83 TAAR1 (0.40) TAAR1CYP3A4PTGS1PTGS2LRRK2
SCHEMBL4460448 0.83 CYP3A4 (0.44) TAAR1CYP3A4KDM4CPTGS1PTGS2
SCHEMBL4457222 0.83 TAAR1 (0.43) TAAR1PTGS2LRRK2GRM2KCNA5
SCHEMBL4461625 0.82 CYP19A1 (0.40) KCNA5KCND3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US claimed
US-20090030043-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-01-29 US disclosed
EP-1981507-A2 POTASSIUM CHANNEL INHIBITORS Merck & Co., Inc. (US) 2008-10-22 EP disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed
WO-2007089679-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090030043-A1 Potassium Channel Inhibitors KCNJ2, KCNH2, KCNH3 TAAR1 560/4885CYP3A4 1307/4885KDM4C 279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.